Thu, May 15, 7:44 PM (38 days ago)
### Propanc Biopharma, Inc. (PPCB) Q1 2025 Financial Summary **Quarterly Financial Health and Performance:** - **Revenue:** No revenue generated for the quarter. - **Profit Margins:** Significant losses with a net loss of $54.1 million for Q1 2025. - **Cash Flow:** Negative cash flow from operations at $378,000. - **Earnings Changes:** Increased net loss compared to Q1 2024. - **Quarterly Performance:** Continued financial struggles with substantial losses and negative cash flow. **Key Financial Metrics:** - **Total Assets:** $22.5 million, primarily cash and prepaid expenses. - **Total Liabilities:** $4.4 million, including convertible debt and accounts payable. - **Stockholders' Equity:** Negative $121.6 million, indicating significant accumulated losses. **Operational Impact:** - **Research and Development:** Continued investment in R&D, focusing on cancer treatments. - **Funding:** Reliance on debt and equity financing to sustain operations. - **Patents:** 84 granted, allowed, or accepted patents, with 6 pending. **Future Operations:** - **Reverse Stock Split:** Effective January 29, 2025, at a ratio of 1:60,000. - **Public Offering:** Plans to uplist on NASDAQ and conduct a public offering. - **Collaborations:** Ongoing research with universities and potential future partnerships. **Uncertainties and Risks:** - **Financial Stability:** Significant doubt about the ability to continue as a going concern. - **Market Risks:** Dependence on debt financing and potential dilution of equity. - **Operational Risks:** Need for additional funding and successful execution of business plan. **Conclusion:** Propanc Biopharma, Inc. faces significant financial challenges, including substantial losses and negative cash flow. The company is reliant on external financing and strategic partnerships to continue operations and advance its cancer treatment research. The reverse stock split and potential public offering are critical steps in securing the necessary funds to sustain and grow the business.